Avila, Sanofi-Aventis Shake Hands on $800M Alliance
By Catherine Shaffer
Tuesday, December 21, 2010
Dazzled by science, Sanofi-Aventis SA, of Paris, plunked down $40 million in up-front cash and committed to as much as $770 million in milestones for collaborative access to Avila Therapeutics Inc.'s covalent drug discovery platform.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.